Dive into the archives.
- Abbott enters final clinical trial of MS drug
Abbott Laboratories and its Massachusetts biotech partner have launched a final-stage clinical trial of their experimental treatment for multiple sclerosis. The first of an eventual 1,500 patients needed worldwide was enrolled last month in the U.S. The drug, daclizumab, is being developed for monthly injection under the patient’s skin by North Chicago-based Abbott and Cambridge-based [...]
- Facet Biotech Announces Daclizumab MS Program to Advance
Aug 03, 2009 16:30 ET REDWOOD CITY, CA–(Marketwire – August 3, 2009) – Facet Biotech Corporation today announced its decision, along with its partner Biogen Idec, to continue planning for the phase 3 trial of daclizumab high-yield process (DAC HYP) in multiple sclerosis (MS). The company plans to request a Special Protocol Assessment from the [...]
- Daclizumab and Interferon: Next Wave Combination Therapy?
Studies are ongoing. This post isn’t hot off the press…
- Daclizumab shows Promise in Phase II Trial
Daclizumab Shows Promise in Phase II Trial for MS Just over a year ago, PDL Pharmaceuticals partnered with MS giant Biogen (Avonex, Tysabri) to bring a drug known as daclizumab through trials for MS. Daclizumab is today used for the prevention of kidney transplant rejection, under the marketing name Zenapax (r). The partnership seems to [...]
